Fig. 4
From: [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma
Images from a 69y-old male patient with a PDAC in the pancreatic tale. Images on the left (a–d) were obtained prior to the onset of chemotherapy, images on the right (e–h) were obtained 14 days later, after two cycles of neoadjuvant chemotherapy with nab-Paclitaxel/gemcitabine. Axial T2 FS (a, e) show no change in tumor size. However, PET showed a significant decrease in MTV50% (56.4%) and TLG50% (53.9%) (b, f). Furthermore, a significant increase in ADCmean (44.8%) was seen (c, g). The bottom row displays the baseline CT (d) as well as the follow-up CT (h) after 5 cycles of nab-Paclitaxel/gemcitabine in the same patient. The follow-up CT was obtained after 81 days. Based on RECIST1.1 the patient was stratified as a responder. Left-sided pancreatic resection with splenectomy was performed after the follow-up CT